Loeffler endocarditis, eosinophilic endocarditis or eosinophilic endomyocardial disease are conditions associated with hypereosinophilia and they affect the heart function. Loeffler endocarditis is a rare endomyocardial disorder thought to be caused by eosinophilic damage. The disorder is characterized by inflammatory infiltration, formation of thrombus within cardiovascular system, and ultimately fibrosis of the afflicted area. It can lead to multiple severe complications, including thromboembolic disease, thickening of fibrous tissue in the endocardium of ventricles, valve involvement, apical obliteration, and various heart disorders. Although early clinical intervention can lead to remission, the underlying mechanisms of the disorder remain unresolved. In the present article, we summarise the existing literature concerning Loeffler endocarditis based on PubMed, Web of Science, and other medical databases to conduct an in-depth review of the epidemiology, etiology, pathophysiological mechanisms, staging, diagnosis, treatment and prognosis of Loeffler endocarditis. Meanwhile, we provide novel patients data and clinical figures of Loeffler endocarditis to supplement the understanding of this cardiac disorder. The findings presented in this article provide a basis for further studies and can be used to improve management of the disorder.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10984210 | PMC |
http://dx.doi.org/10.2147/JIR.S458692 | DOI Listing |
Ann Allergy Asthma Immunol
December 2024
Department of Pediatrics, Division of Allergy and Pulmonary Medicine, Washington University School of Medicine, Saint Louis, MO; Department of Pediatrics, Division of Rheumatology/Immunology, Washington University School of Medicine, Saint Louis, MO. Electronic address:
Intern Med J
December 2024
Department of Paediatrics, Fiona Stanley Hospital, Perth, Western Australia, Australia.
Background: The frequency of EoE has been increasing in Northern Hemisphere cohorts, yet there is a scarcity of data in our region. Regional climatic factors, and lifestyle habits may influence the presentation of EoE, and appropriate management is crucial to prevent complications. WIth this is mind we undertook the first comprehensive multisite study of EoE in Australasian children.
View Article and Find Full Text PDFNed Tijdschr Geneeskd
December 2024
Meander Medisch Centrum, Amersfoort. Afd. Longgeneeskunde.
Eosinophilia is a common laboratory finding with a broad differential diagnosis. Eosinophilia can be classified as primary, secondary, or idiopathic hypereosinophilic syndrome (HES). Primary eosinophilia results from a clonal disorder of eosinophils, while secondary eosinophilia is reactive to a variety of underlying conditions, such as allergic diseases, infections, and drug reactions.
View Article and Find Full Text PDFTher Adv Respir Dis
December 2024
Department of Medicine and Surgery, University of Insubria, Varese, Italy.
Background: Benralizumab is a monoclonal antibody treatment for severe eosinophilic asthma (SEA). Few studies investigated its role in airway inflammation and its correlation with lung function.
Objectives: The aim of the present study is to assess its effect after 1 year of treatment, focusing on airway inflammation.
Eur Heart J Case Rep
October 2024
Baker Heart and Diabetes Institute, Melbourne, Victoria 3004, Australia.
Background: Fulminant eosinophilic myocarditis (EM) is a rare and often fatal condition that may present atypically and be complicated by ventricular arrhythmias. Treatment involves high-dose corticosteroids to suppress eosinophilia, as well as increasing use of mepolizumab, an anti-interleukin-5 antibody with evidence for long-term efficacy and safety.
Case Summary: A 38-year-old woman presented to the emergency department with neck pain and fatigue, and after extensive investigation was diagnosed with EM secondary to idiopathic hypereosinophilic syndrome.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!